CAMP4 THERAPEUTICS CORPORATION
$4.51
▲
0.22%
2026-04-21 05:53:00
www.camp4tx.com
NGM: CAMP
Explore CAMP4 THERAPEUTICS CORPORATION stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$233.12 M
Current Price
$4.51
52W High / Low
$7.75 / $1.3
Stock P/E
—
Book Value
$0.92
Dividend Yield
—
ROCE
-50.89%
ROE
-1.45%
Face Value
—
EPS
$-2.65
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
48
Beta
—
Debt / Equity
4.2
Current Ratio
7.35
Quick Ratio
7.35
Forward P/E
-6.35
Price / Sales
66.64
Enterprise Value
$125.6 M
EV / EBITDA
-2.49
EV / Revenue
35.91
Rating
Strong Buy
Target Price
$8.2
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 2. | MacroGenics, Inc. | $3.48 | — | $228.17 M | — | -34.08% | -86.94% | $3.88 / $1.11 | $0.88 |
| 3. | Alpha Cognition Inc. Common Stock | $6.89 | — | $150.02 M | — | -23.03% | -40.68% | $11.54 / $3.97 | $2.88 |
| 4. | Ocular Therapeutix, Inc. | $9.52 | — | $2.09 B | — | -35.66% | -54.85% | $16.44 / $6.23 | $3.03 |
| 5. | Zenas BioPharma, Inc. | $20.9 | — | $1.28 B | — | -65.85% | -1.36% | $44.6 / $8.09 | $4.44 |
| 6. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 7. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.35 M | 0.8 M | 1.5 M | 0.86 M | 0.65 M | — |
| Operating Profit | -12.78 M | -13.16 M | -13.03 M | -13.1 M | -14.03 M | — |
| Net Profit | -40.28 M | -15.1 M | -12.59 M | -12.43 M | -13.28 M | — |
| EPS in Rs | -0.78 | -0.29 | -0.24 | -0.24 | -0.26 | -0.69 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 3.5 M | 0.65 M | 0.35 M | 0 M |
| Operating Profit | -52.06 M | -53.09 M | -51.88 M | -45 M |
| Net Profit | -80.4 M | -51.79 M | -49.29 M | -44.19 M |
| EPS in Rs | -1.55 | -1 | -0.95 | -0.85 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 117.81 M | 78.31 M | 54.95 M | 102.55 M |
| Total Liabilities | 70.1 M | 15.16 M | 178.68 M | 180.08 M |
| Equity | 47.7 M | 63.14 M | -123.73 M | -77.53 M |
| Current Assets | 114.09 M | 66.38 M | 40.01 M | 84.41 M |
| Current Liabilities | 15.51 M | 9.6 M | 7.81 M | 7.95 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -29.55 M | -45.56 M | -44.16 M | -38.54 M |
| Investing CF | -0.24 M | -0.44 M | -0.68 M | -4.03 M |
| Financing CF | 75.89 M | 71.66 M | 0.3 M | 100.16 M |
| Free CF | -29.83 M | -46 M | -44.83 M | -42.57 M |
| Capex | -0.28 M | -0.44 M | -0.68 M | -4.03 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | 436.5% | 86.29% | — | — |
| Earnings Growth % | -55.25% | -5.07% | -11.54% | — |
| Profit Margin % | -2298.54% | -7943.4% | -14083.14% | — |
| Operating Margin % | -1488.31% | -8142.33% | -14822.57% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1441.45% | -7882.21% | -14343.14% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.